Cargando…
Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477633/ https://www.ncbi.nlm.nih.gov/pubmed/37675308 http://dx.doi.org/10.21037/atm-23-597 |
| _version_ | 1785101175204347904 |
|---|---|
| author | Egger, Michael E. |
| author_facet | Egger, Michael E. |
| author_sort | Egger, Michael E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10477633 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104776332023-09-06 Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden Egger, Michael E. Ann Transl Med Editorial Commentary AME Publishing Company 2023-03-03 2023-08-30 /pmc/articles/PMC10477633/ /pubmed/37675308 http://dx.doi.org/10.21037/atm-23-597 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Egger, Michael E. Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title | Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title_full | Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title_fullStr | Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title_full_unstemmed | Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title_short | Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| title_sort | identifying high-risk stage iiia cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477633/ https://www.ncbi.nlm.nih.gov/pubmed/37675308 http://dx.doi.org/10.21037/atm-23-597 |
| work_keys_str_mv | AT eggermichaele identifyinghighriskstageiiiacutaneousmelanomapatientswhomightbenefitfromadjuvanttherapytheimportanceofmicrometastatictumorburden |